Clinical Trial News and Research

RSS

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Screening for breast cancer risk in all postmenopausal women, using a combination of risk factors and breast density, can identify women at high risk of disease, according to systematic literature reviews and meta-analyses reported in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Study methods influence estimates of lead time and overdiagnosis in prostate cancer

In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Immune-based therapy approved in Europe for pediatric cancer patients

The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.

11 Mar 2009

Folic acid appears to double risk for prostate cancer

A study led by researchers at the University of Southern California (USC) found that men who took a daily folic acid supplement of 1 mg daily had more than twice the risk of prostate cancer compared with men who took a placebo.

11 Mar 2009

A vaccine for multiple sclerosis

Apitope Technology Ltd is a biopharmaceutical company that specialises in developing treatments for allergy and autoimmune diseases.

11 Mar 2009

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009

Advances in stem cell research

Scientists at The University of Texas Health Science Center at Houston are on the forefront of stem cell research, developing novel therapies designed to generate heart cells, repair traumatic lung injuries, grow new bone and stanch the spread of cancer cells.

8 Mar 2009

Vaginal microbicide gel shows promise as HIV prevention method for women

A clinical trial involving more than 3,000 women in the U.S. and southern Africa demonstrates for the first time the promise of a vaginal microbicide gel for preventing HIV infection in women.

5 Mar 2009

Folic acid, B vitamins in Animi-3 may prevent vision loss

A new study by researchers at Harvard Medical School has found that combining essential B vitamins, including B6, B12, and folic acid, lower risk of developing age-related macular degeneration (AMD), one of the leading causes of vision loss among older Americans.

4 Mar 2009

Cordex Pharma files ATPace formulation patent

Cordex Pharma, Inc. has announced today that it has filed a formulation patent covering its lead product, ATPace.

4 Mar 2009

Regular moderate alcohol intake associated with greater bone mineral density

Researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University found associations were strongest for beer and wine and, importantly, BMD was significantly lower in men drinking more than two servings of liquor per day.

3 Mar 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Aerovance starts trial of Aerovant for uncontrolled asthma

Aerovance Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

3 Mar 2009

New implantable lenses put high-tech devices within reach, UT Southwestern eye surgeons say

If you're having trouble reading or sending text messages on your new cell phone, UT Southwestern Medical Center eye surgeons may have a remedy.

3 Mar 2009

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

Angiogenesis inhibitors, study points to limitations, solutions

A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals.

2 Mar 2009

New optical technology shows promise in detecting pancreatic cancer

Optical technology developed by a Northwestern University professor of biomedical engineering has been shown to be effective in detecting the presence of pancreatic cancer through analysis of neighboring tissue in the duodenum, according to clinical trial results published in the journal Disease Markers.

2 Mar 2009

Experimental drug fampridine improves mobility for some MS patients

In MS, the body's immune system attacks myelin, a fatty tissue that wraps and insultates nerve fibers, disrupting the transmission of signals in the central nervous system.

1 Mar 2009

Lab tests show meropenem and clavulanate combination effective against drug-resistant TB bacteria

WHAT: In a finding that could soon help people infected with untreatable, highly drug-resistant tuberculosis (TB), scientists have shown that two FDA-approved drugs work in tandem to kill laboratory-grown strains of Mycobacterium tuberculosis (Mtb), the bacterium that causes TB.

26 Feb 2009

VIA Pharmaceuticals awarded new patent on lead compound VIA-2291

VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.

25 Feb 2009